查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1848803

早產和胎膜早破檢測市場（按產品類型、最終用戶和應用）—2025-2032 年全球預測

Preterm Birth & PROM Testing Market by Product Type, End User, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，早產和胎膜早破檢測市場將成長 27 億美元，複合年成長率為 6.42%。

主要市場統計數據
基準年2024年 16.4億美元
預計2025年 17.4億美元
預測年份：2032年 27億美元
複合年成長率（%） 6.42%

動態介紹醫療保健領域早產和胎膜早破檢測的臨床重點、診斷工作流程和操作壓力

早產和胎膜早破 (PROM) 檢測處於產科、新生兒科和診斷創新的交叉領域。臨床醫生越來越依賴客觀的生物標記和改進的檢測工作流程來做出影響產婦和新生兒結局的時效性決策。同時，實驗室主任和採購團隊面臨著在將新平台整合到現有診斷生態系統的同時，平衡準確性、通量和成本的壓力。

在臨床實踐中，早期準確識別胎膜早破 (PROM) 和先兆早產可對診療路徑產生重大影響，包括決定使用皮質類固醇、抗生素、強心劑以及轉運至更高危重症中心。因此，能夠在靠近患者和實驗室的環境中提供快速可靠結果的創新技術正受到臨床領導者的廣泛關注。同時，監管審查和循證指南的更新正在重塑人們對檢測驗證、臨床效用證明和上市後監測的期望。

從操作角度來看，診斷領域正朝著模組化工作流程發展，以支援周產期，對於實施具有臨床意義且操作永續的檢測通訊協定至關重要。總而言之，這些動態凸顯了診斷檢測創新在改善產前護理途徑和減少後續新生兒併發症方面將發揮的關鍵作用。

技術、證據和供應鏈的最新變化如何重塑檢測早產風險和胎膜早破的診斷策略

近年來，早產風險和胎膜早破（PROM）的識別、監測和管理方式發生了重大變化。分子診斷、免疫檢測和照護現場技術的進步，在不犧牲分析性能的情況下實現了更快的反應時間。同時，數位健康平台和實驗室資訊系統改進了資料整合，使臨床醫生能夠將生物標記結果與電子健康記錄趨勢和決策支援演算法相結合。這些發展提高了臨床醫生對快速、可操作診斷結果的期望。

此外，診斷領域正更加重視臨床效用和真實世界檢驗研究。開發者和應用者擴大尋求真實世界證據，將檢測結果與患者管理和預後方面的可衡量變化聯繫起來，而不是僅僅依賴實驗室績效指標。這種轉變正在推動檢測製造商和臨床研究人員之間更緊密的合作，以設計能夠證明有意義的臨床終點的試驗。

同時，供應鏈彈性和試劑永續性已成為策略重點。檢測開發商正在投資試劑穩定性、替代籌資策略和耗材標準化，以減少營運中斷。因此，採用決策不僅取決於分析準確性，還取決於長期供應的連續性和整合的便利性。這些綜合變化正在重塑臨床和實驗室相關人員的產品藍圖和籌資策略。

了解不斷變化的關稅政策和進口成本壓力將如何影響診斷測試供應鏈的彈性、採購策略以及 2025 年前的部署時間表

2025年的關稅環境為診斷製造商、經銷商和醫療保健採購組織帶來了層層複雜性。更高的進口關稅和關稅分類的變化可能會增加儀器、套件和試劑的到岸成本，迫使組織重新評估籌資策略和供應商多元化。這促使一些製造商加快本地化生產或尋找替代供應商，以降低風險並保持利潤率穩定。

採購領導者越來越關注總擁有成本 (TCO) 和合約機制，以規避關稅波動的影響。例如，隨著相關人員尋求可預測性，包含固定價格條款的多年期供應協議、聯合庫存規劃以及在需求預測方面的密切合作已變得司空見慣。同時，診斷公司也在尋求關稅工程——調整材料清單、組裝流程、原產國文件等——以在不影響合規性的前提下最大限度地降低關稅的影響。

重要的是，這些與關稅相關的應對措施對臨床部署週期產生了次要影響。設備出貨前置作業時間延長以及試劑供應有限，可能會延遲診斷實驗室的驗證活動，並減緩新檢測在門診和住院環境中的部署。因此，衛生系統和實驗室越來越重視緊急時應對計畫和靈活的驗證通訊協定，以確保即使在供應鏈中斷的情況下也能持續提供臨床服務。這些調整正在重塑整個診斷生態系統的採購策略和創新時間表。

細分主導的洞察，了解產品架構、最終用戶需求和應用優先順序如何決定採用模式和籌資策略

詳細的細分分析揭示了不同產品類型、最終用戶和應用在技術採用和使用模式上的顯著差異。按產品類型分類，自動化 ELISA 分析儀、免疫檢測分析儀和 PCR 系統等儀器和設備通常優先用於高通量診斷實驗室和大型醫院系統，因為這些系統的通量、準確性以及與實驗室自動化的整合至關重要。相較之下，ELISA套件、PCR 檢測試劑檢測套組和快速檢測套組等試劑套件和檢測方法的應用範圍更為廣泛。 ELISA 和 PCR套件套件通常支援集中式實驗室工作流程，而快速檢測套組則能夠在門診和醫院分流中更貼近患者地做出決策。

試劑和耗材，包括抗體、緩衝液、培養基、酵素和探針，是經常性的營運支出，推動採購和庫存策略的發展。門診護理優先考慮易用性和速度，診斷實驗室強調通量和分析穩定性，醫院和診所需要擴充性並與臨床工作流程相容，而研究機構通常需要可客製化的試劑和靈活性來支援探索性檢測。需求概況進一步細分：診斷案例要求監管級別的驗證和可重複性，監測用例強調序列採樣和縱向解讀，研究用例優先考慮實驗靈活性，而篩檢則要求高通量、成本效益和最低的假陽性率。

總的來說，產品架構、最終用戶操作限制和預期用途之間的相互作用將決定產品開發的優先順序、市場區隔以及整個診斷價值鏈的商業夥伴關係關係結構。

區域診斷格局和醫療保健系統的細微差別影響了美洲、歐洲、中東和非洲地區以及亞太地區的採用、報銷和部署策略

區域動態顯著影響早產和胎膜早破檢測的診斷採用途徑、報銷框架和途徑整合。在美洲，臨床決策受到私人和公共支付機構、區域卓越中心以及對醫院和實驗室整合的關注。這種環境有利於擴充性的設備平台和檢驗套件，這些試劑盒可在綜合醫療系統中部署，同時也支持學術中心的社區創新。

歐洲、中東和非洲地區 (EMEA) 的特點是監管環境和醫療保健津貼模式各異，導致各國的採用率不一。雖然集中式報銷系統和完善的臨床指南正在加速許多西方市場採用經過驗證的診斷檢測，但在其他地區，由於醫療保健預算有限和物流障礙，低成本快速檢測和本地化試劑解決方案受到青睞。此外，區域合作和跨境研究夥伴關係在證據產生和指南協調方面發揮著日益重要的作用。

亞太地區擁有蓬勃發展的高所得醫療保健體系和龐大的新興市場。快速的都市化和孕產婦保健服務的普及，推動了對高通量實驗室解決方案和分散式檢查模式的需求。旨在加強周產期保健基礎設施的本地製造地和政府支持的舉措正在加速產品本地化和官民合作關係。在所有地區，相關人員一致認為，需要臨床效用證據、與護理途徑的無縫整合以及具有韌性的供應鏈，以確保關鍵診斷檢測的持續可及性。

競爭、夥伴關係策略和基於證據的差異化將決定哪些公司將在早產和胎膜早破診斷創新方面處於領先地位

早產和胎膜早破 (PROM) 檢測領域的競爭動態由眾多知名診斷製造商、專業試劑供應商以及將照護現場功能推向市場的敏捷創新者共同塑造。現有儀器製造商繼續在平台可靠性、與實驗室自動化的兼容性以及全球服務網路方面競爭，而新參與企業則憑藉利基檢測化學技術、簡化的用戶界面和快速部署模式脫穎而出。儀器製造商和檢測開發商之間的戰略夥伴關係和共同開發契約正在不斷增多，從而加快了市場准入速度並共用了監管途徑。

那些擁有穩定品質、可靠供應鏈和臨床實驗室最佳化包裝的試劑和耗材供應商正成為採購團隊的首選。同時，投資臨床檢驗計畫並檢驗真實世界證據的公司不僅可以證明分析準確性，還可以證明其對治療決策的可衡量影響，從而加速臨床醫生的採納。此外，經銷商關係、醫院直銷以及實驗室網路協定等通路動態也會影響跨地區的覆蓋範圍和應用。

總體而言，競爭優勢將越來越取決於將技術性能與營運彈性和基於證據的臨床價值相結合的能力，這為能夠整合整個診斷生態系統並在從部署到上市後監測的整個生命週期內為客戶提供支援的公司創造了機會。

診斷製造商和醫療保健領導者制定了可行的策略重點，重點是驗證、彈性供應鏈、靈活的商業模式和付款人參與

產業領導者應優先考慮多管齊下的策略，將產品創新與臨床檢驗、供應鏈穩健性和付款人參與度結合。首先，投資於實用臨床研究，以證明診斷結果如何改變管理決策並改善孕產婦和新生兒的預後，這對於確保臨床醫生的認可和支持報銷討論至關重要。此類研究的設計應考慮現實世界的工作流程，並結合多中心合作以增強普適性。

其次，透過雙重採購、多元化生產地點以及對試劑長期穩定性的承諾來增強供應鏈的韌性，可以降低營運風險並增強客戶信心。同時，提供靈活的商業模式，例如試劑即服務、試劑設備租賃協議或捆綁式實施包，可降低醫療保健系統和實驗室的採用門檻。

第三，領導者應積極與付款方、指南制定機構和醫院採購委員會合作，展示其超越檢測準確性的價值提案，並強調在有證據支持的情況下，避免下游成本、降低新生兒發病率並改善護理路徑。最後，培育可互通的平台和開放資料標準將有助於與醫院系統的整合，並實現增值分析，從而增強檢測結果的臨床效用。透過採取這些互補的行動，製造商和相關人員可以加快採用速度，同時降低商業性和營運風險。

結合主要專家訪談、技術文獻和臨床文獻整合的嚴格方法檢驗了診斷性能和實施考慮

本分析整合了同行評審的臨床文獻、監管指南文件、行業可用的技術規格以及對臨床醫生、實驗室主任和採購專業人員的初步訪談。該方法優先考慮三角測量，將分析性能證據與從實際實踐中獲得的臨床效用和操作實施的見解相結合。在與監管指南相關的方面，我們關注的是指南如何指導驗證需求和上市後監管，而不是特定司法管轄區的合規性檢查清單。

初步研究包括與產科、新生兒科、檢驗醫學和醫院營運專家進行的結構化訪談。次要研究包括關於檢測性能的方法論論文、已發表的關於早產兒恢復（PROM）及其早產診斷相關結局的臨床研究，以及詳細說明平台功能和耗材要求的供應商技術文件。數據整合強調了不同資訊來源主題的一致性，並指出了存在分歧的領域，以突出不確定性和有針對性地產生證據的機會。

調查方法的局限性包括臨床文獻中研究設計和終點的差異性、不同地區採用途徑的異質性以及可能改變採購獎勵的政策動態變化。為了克服這些局限性，我們透過多位專家訪談檢驗了研究結果，並與產品技術文獻進行了交叉引用，以確保充分體現實際採用方面的考慮。

對診斷創新、證據預期和業務重點的總結性綜合，將決定早產和胎膜早破檢測的未來發展方向

摘要，在技術進步、更高的證據期望和業務需求的推動下，早產和胎膜早破（PROM）檢測的診斷領域正在迅速發展。臨床醫生和實驗室負責人正在尋求不僅能證明分析可靠性，還能證明臨床療效並且能夠無縫整合到護理路徑中的診斷方法。供應鏈的連續性和與關稅相關的成本壓力正在推動採購和合約設計的策略轉變，從而影響部署和檢驗的時間表。

細分洞察表明，儀器和高通量平台仍將是醫院和實驗室策略的核心，而套件和照護現場套件將擴大門診和急診分流的可及性。試劑和耗材將繼續影響目前的採購動態，而診斷、監測、研究用途和篩檢領域的應用將對驗證和工作流程整合產生差異化的要求。從地理上看，報銷、法律規範和區域製造能力的相互作用將繼續創造多樣化的採用路徑。

對於尋求推進產前檢測的利害關係人相關人員，強力的臨床檢驗、靈活透明的交付模式以及與支付方和指南委員會的密切合作是明確的優先事項。這些優先事項將決定哪些創新技術能夠實現永續的臨床應用，並改善孕產婦和新生兒的預後。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 在門診護理中擴大採用快速床邊生化標記進行早期胎膜早破檢測
  • 將預測分析與遠端胎兒監測平台結合，以評估早產風險
  • 用於篩檢妊娠中期早產阻塞性卵巢症候群（PROM）的非侵入性蛋白質體學檢測的開發和臨床實施
  • 人工智慧超音波影像成像技術的投資正在增加，以提高早產預測的準確性
  • 擴展基於生物標記的家用檢測套組，以便患者主導早期檢測胎膜破裂風險
  • 監管核准趨勢和不斷演變的報銷框架推動了高級 PROM 診斷的普及
  • 學術研究中心與診斷公司合作檢驗不同族群的新型早產生物標記物

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第 8 章早產和胎膜早破檢測市場（依產品類型）

  • 設備和設施
    • 全自動ELISA分析儀
    • 免疫檢測分析儀
    • PCR體系
  • 套件和檢測試劑套件
    • 酵素連結免疫吸附測定試劑套件
    • PCR檢測套組
    • 快速檢測套組
  • 試劑和耗材
    • 抗體
    • 緩衝液和介質
    • 酵素和探針

第9章早產及胎膜早破檢測市場（依最終用戶分類）

  • 門診治療
  • 診斷實驗室
  • 醫院和診所
  • 研究機構

第 10 章早產和胎膜早破檢測市場（按應用）

  • 診斷
  • 監控
  • 研究用途
  • 篩檢

第 11 章早產和胎膜早破檢測市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 12 章早產和胎膜早破檢測市場（按群體）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 13 章早產和胎膜早破檢測市場（按國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Roche Diagnostics GmbH
    • Abbott Laboratories
    • Hologic, Inc.
    • Quidel Corporation
    • Danaher Corporation
    • Thermo Fisher Scientific Inc.
    • bioMerieux SA
    • Sekisui Medical Co., Ltd.
    • Sera Prognostics, Inc.
    • Rhomed SpA
Product Code: MRR-42653751E7E1

The Preterm Birth & PROM Testing Market is projected to grow by USD 2.70 billion at a CAGR of 6.42% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.64 billion
Estimated Year [2025] USD 1.74 billion
Forecast Year [2032] USD 2.70 billion
CAGR (%) 6.42%

A dynamic introduction to clinical priorities, diagnostic workflows, and operational pressures shaping preterm birth and PROM testing across healthcare settings

Preterm birth and premature rupture of membranes (PROM) testing sit at the intersection of obstetrics, neonatal care, and diagnostic innovation. Clinicians increasingly rely on objective biomarkers and improved testing workflows to make time-sensitive decisions that affect maternal and neonatal outcomes. Meanwhile, laboratory directors and procurement teams face mounting pressure to balance accuracy, throughput, and cost while integrating new platforms into existing diagnostic ecosystems.

In clinical practice, early and precise identification of PROM and imminent preterm delivery can materially influence treatment pathways, including administration of corticosteroids, antibiotics, tocolytics, and decisions regarding transfer to higher-acuity centers. As a result, innovations that deliver rapid, reliable results in near-patient and laboratory settings are drawing significant attention from clinical leaders. Concurrently, regulatory scrutiny and evidence-based guideline updates are reshaping the expectations for test validation, clinical utility demonstrations, and post-market surveillance.

From an operational perspective, the diagnostic landscape is evolving toward modular workflows that support high-volume laboratory automation as well as decentralized testing at ambulatory and hospital sites. Cross-disciplinary collaboration among obstetricians, perinatologists, laboratorians, and hospital administrators is becoming central to implementing testing protocols that are clinically meaningful and operationally sustainable. Taken together, these dynamics underscore the critical role of diagnostic testing innovation in improving prenatal care pathways and reducing downstream neonatal complications.

How recent technological, evidence, and supply chain shifts are reshaping diagnostic strategies for detecting preterm birth risks and premature rupture of membranes

Recent years have seen a transformative shift in how preterm birth risk and PROM are identified, monitored, and managed. Advances in molecular diagnostics, immunoassays, and point-of-care technologies have enabled faster turnaround times without sacrificing analytical performance. Concurrently, digital health platforms and laboratory information systems are improving data integration, enabling clinicians to combine biomarker results with electronic health record trends and decision support algorithms. These developments have collectively raised clinician expectations for rapid, actionable diagnostic outputs.

Moreover, the diagnostic community has moved toward greater emphasis on clinical utility and pragmatic validation studies. Rather than relying solely on laboratory performance metrics, developers and adopters increasingly demand real-world evidence that links test results to measurable changes in patient management and outcomes. This shift has prompted closer engagement between test manufacturers and clinical investigators to design studies that demonstrate meaningful clinical endpoints.

At the same time, supply chain resilience and reagent sustainability have emerged as strategic priorities. Test developers are investing in reagent stabilization, alternative sourcing strategies, and consumable standardization to reduce operational disruptions. Consequently, adoption decisions now factor not just analytical accuracy but also long-term supply continuity and integration ease. Together, these shifts are reshaping product roadmaps and procurement strategies across clinical and laboratory stakeholders.

Understanding how evolving tariff policies and import cost pressures in 2025 are impacting supply chain resilience, procurement tactics, and deployment timelines for diagnostic testing

The tariff environment entering into 2025 introduced a layer of complexity for diagnostic manufacturers, distributors, and healthcare purchasing organizations. Increased import duties and changes to customs classifications have the potential to elevate landed costs for instruments, kits, and reagents, prompting organizations to reassess sourcing strategies and supplier diversification. In response, some manufacturers accelerated localization of manufacturing or qualified alternate suppliers to mitigate exposure and preserve margin stability.

Procurement leaders have reacted by increasing focus on total cost of ownership and contractual mechanisms that hedge against tariff volatility. For example, multi-year supply agreements with fixed pricing clauses, joint inventory planning, and closer collaboration on demand forecasting have become more common as stakeholders seek predictability. In parallel, diagnostic companies have explored tariff engineering-adjusting bill of materials, assembly processes, or country-of-origin documentation-to minimize the tariff impact without compromising compliance.

Importantly, these tariff-related responses have secondary effects on clinical deployment cycles. Extended lead times for instrument shipments and constrained reagent availability can delay validation activities in diagnostic laboratories and slow rollout of new tests in ambulatory and hospital settings. Consequently, health systems and laboratories are placing greater emphasis on contingency planning and flexible validation protocols so clinical service continuity is preserved when supply chain interruptions occur. These adaptations are reshaping procurement playbooks and innovation timelines across the diagnostic ecosystem.

Segmentation-driven insights into how product architectures, end-user needs, and application priorities determine adoption patterns and procurement strategies

A granular segmentation analysis reveals meaningful differences in technology adoption and usage patterns across product types, end users, and applications. Within product types, instruments and equipment such as automated ELISA analyzers, immunoassay analyzers, and PCR systems are typically prioritized by high-throughput diagnostic laboratories and larger hospital systems where throughput, precision, and integration with laboratory automation are paramount. In contrast, kits and assay formats including ELISA kits, PCR test kits, and rapid test kits serve a broader array of settings; ELISA and PCR kits often underpin centralized laboratory workflows while rapid test kits enable near-patient decision-making in ambulatory care or hospital triage.

Reagents and consumables, encompassing antibodies, buffers and media, and enzymes and probes, represent the recurring operational spend that drives procurement and inventory strategies. End users differ in their procurement and validation imperatives: ambulatory care settings typically prioritize ease of use and rapid turnaround, diagnostic laboratories emphasize throughput and analytical robustness, hospitals and clinics require scalability and compatibility with clinical workflows, and research institutes often seek customizable reagents and the flexibility to support exploratory assays. Applications further segment the demand profile, as diagnostic use cases demand regulatory-grade validation and reproducibility, monitoring applications focus on serial sampling and longitudinal interpretation, research use prioritizes experimental flexibility, and screening requires high throughput, cost-effectiveness, and minimal false-positive rates.

Taken together, the interplay among product architecture, end-user operational constraints, and intended application informs product development priorities, go-to-market segmentation, and the structure of commercial partnerships across the diagnostic value chain.

Regional diagnostic landscapes and healthcare system nuances that shape adoption, reimbursement, and deployment strategies across the Americas, EMEA, and Asia-Pacific

Regional dynamics materially influence diagnostic adoption pathways, reimbursement frameworks, and pathway integration for preterm birth and PROM testing. In the Americas, clinical decision-making is shaped by a mix of private and public payers, regional centers of excellence, and a strong emphasis on hospital and laboratory consolidation. This environment favors scalable instrument platforms and validated kits that can be deployed across integrated health systems, while also supporting localized innovation in academic centers.

Europe, Middle East & Africa features diverse regulatory landscapes and variable healthcare funding models, which create heterogenous adoption rates across countries. In many Western European markets, centralized reimbursement and robust clinical guidelines accelerate uptake of validated diagnostic tests, whereas in other parts of the region, constrained healthcare budgets and logistical barriers prioritize low-cost rapid tests and locally adaptable reagent solutions. Additionally, regional collaborations and cross-border research partnerships are playing an increasing role in evidence generation and guideline harmonization.

Asia-Pacific encompasses a fast-adopting mix of high-income healthcare systems and large emerging markets, where rapid urbanization and expanding prenatal care access drive demand for both high-throughput laboratory solutions and decentralized testing models. Local manufacturing hubs and government-supported initiatives aimed at strengthening perinatal care infrastructures are accelerating product localization and public-private partnerships. Across all regions, stakeholders are converging on the need for evidence of clinical utility, seamless integration into care pathways, and resilient supply chains to ensure continuous access to critical diagnostic testing.

Competitive forces, partnership strategies, and evidence-driven differentiation that determine which companies lead in preterm birth and PROM diagnostic innovation

Competitive dynamics in the preterm birth and PROM testing space are shaped by a mix of established diagnostics companies, specialized reagent suppliers, and agile innovators bringing point-of-care capabilities to market. Incumbent instrument manufacturers continue to compete on platform reliability, laboratory automation compatibility, and global service networks, while newer entrants differentiate through niche assay chemistries, simplified user interfaces, and rapid deployment models. Strategic partnerships and co-development agreements between instrumentation firms and assay developers have increased, enabling faster market entry and shared regulatory pathways.

Reagent and consumable suppliers that demonstrate consistent quality, validated supply chains, and packaging formats optimized for clinical laboratories gain preference among procurement teams. Meanwhile, companies that invest in clinical validation programs and publish real-world evidence can accelerate clinician adoption by proving not only analytical accuracy but also measurable impact on care decisions. Additionally, channel dynamics such as distributor relationships, direct sales to hospitals, and laboratory network agreements influence reach and uptake across geographies.

Overall, competitive advantage increasingly depends on the ability to align technical performance with operational resilience and evidence-based clinical value, creating opportunities for firms that can integrate across the diagnostic ecosystem and support customers across the lifecycle from implementation to post-market surveillance.

Actionable strategic priorities for diagnostic manufacturers and healthcare leaders focused on validation, resilient supply chains, flexible commercial models, and payer engagement

Industry leaders should prioritize a multi-pronged strategy that aligns product innovation with clinical validation, supply chain robustness, and payer engagement. First, investing in pragmatic clinical studies that demonstrate how diagnostic results change management decisions and improve maternal and neonatal outcomes will be critical to securing clinician buy-in and supporting reimbursement discussions. These studies should be designed with real-world workflows in mind and incorporate multicenter collaborations to enhance generalizability.

Second, strengthening supply chain resilience through dual sourcing, geographic diversification of manufacturing, and longer-term reagent stability initiatives will reduce operational risk and improve customer confidence. In parallel, offering flexible commercial models-such as reagent-as-a-service, reagent rental agreements for instruments, or bundled implementation packages-can lower adoption barriers for health systems and laboratories.

Third, leaders should engage proactively with payers, guideline-setting bodies, and hospital procurement committees to demonstrate the value proposition beyond test accuracy, highlighting downstream cost avoidance, reduced neonatal morbidity, and improved care pathways where evidence supports those outcomes. Finally, fostering interoperable platforms and open data standards will ease integration with hospital systems and enable value-added analytics that amplify the clinical utility of test results. By pursuing these complementary actions, manufacturers and stakeholders can accelerate adoption while mitigating commercial and operational risks.

A rigorous methodology combining primary expert interviews, technical documentation, and clinical literature synthesis to validate diagnostic performance and implementation considerations

This analysis synthesizes peer-reviewed clinical literature, regulatory guidance documents, industry-available technical specifications, and primary interviews with clinicians, laboratory directors, and procurement professionals. The approach prioritized triangulation, combining evidence of analytical performance with insights about clinical utility and operational implementation drawn from real-world practice. Where regulatory guidance was relevant, interpretations focused on how guidance informs validation needs and post-market surveillance rather than on jurisdiction-specific compliance checklists.

Primary research included structured interviews with subject-matter experts across obstetrics, neonatology, clinical laboratory science, and hospital operations. Secondary research reviewed methodological papers on assay performance, published clinical studies examining outcomes related to PROM and preterm birth diagnostics, and supplier technical documentation that details platform capabilities and consumable requirements. Data synthesis emphasized thematic consistency across sources, and areas of divergent opinion are noted to highlight uncertainties and opportunities for targeted evidence generation.

Limitations of the methodology include variability in study designs and endpoints within the clinical literature, heterogeneity in local adoption pathways across regions, and evolving policy dynamics that may alter procurement incentives. To mitigate these limitations, findings were validated through multiple expert interviews and cross-checked against technical product literature to ensure that practical implementation considerations are well represented.

Concluding synthesis of diagnostic innovation, evidence expectations, and operational priorities that determine the future trajectory of preterm birth and PROM testing

In summary, the diagnostic landscape for preterm birth and PROM testing is undergoing rapid evolution driven by technological advances, higher evidentiary expectations, and operational imperatives. Clinicians and laboratory leaders are seeking diagnostics that deliver not only analytical reliability but also demonstrable clinical impact and seamless integration into care pathways. Supply chain continuity and tariff-related cost pressures are prompting strategic shifts in sourcing and contract design, affecting timelines for deployment and validation.

Segmentation insight indicates that instruments and high-throughput platforms will remain central to hospital and laboratory strategies, while rapid and point-of-care kits will expand access in ambulatory settings and emergency triage. Reagents and consumables continue to shape recurring procurement dynamics, and applications spanning diagnosis, monitoring, research use, and screening create differentiated requirements for validation and workflow integration. Regionally, the interplay of reimbursement, regulatory frameworks, and local manufacturing capacity will continue to produce heterogeneous adoption pathways.

For stakeholders intent on advancing prenatal diagnostics, the clear priorities are robust clinical validation, resilient and transparent supply models, and closer engagement with payers and guideline committees. These priorities will determine which innovations translate into sustainable clinical uptake and improved maternal and neonatal outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of rapid point-of-care biochemical markers for early PROM detection in outpatient settings
  • 5.2. Integration of telehealth fetal monitoring platforms with predictive analytics for preterm labor risk assessment
  • 5.3. Development and clinical adoption of non-invasive proteomic assays for second-trimester preterm PROM screening
  • 5.4. Growing investment in AI-driven ultrasound imaging enhancements to improve preterm birth prediction accuracy
  • 5.5. Expansion of biomarker-based home testing kits enabling patient-managed early detection of membrane rupture risk
  • 5.6. Regulatory approval trends and evolving reimbursement frameworks driving access to advanced PROM diagnostics
  • 5.7. Collaboration between academic research centers and diagnostic firms to validate novel preterm birth biomarkers in diverse populations

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Preterm Birth & PROM Testing Market, by Product Type

  • 8.1. Instruments & Equipment
    • 8.1.1. Automated Elisa Analyzers
    • 8.1.2. Immunoassay Analyzers
    • 8.1.3. Pcr Systems
  • 8.2. Kits & Assay Kits
    • 8.2.1. Elisa Kits
    • 8.2.2. Pcr Test Kits
    • 8.2.3. Rapid Test Kits
  • 8.3. Reagents & Consumables
    • 8.3.1. Antibodies
    • 8.3.2. Buffers & Media
    • 8.3.3. Enzymes & Probes

9. Preterm Birth & PROM Testing Market, by End User

  • 9.1. Ambulatory Care
  • 9.2. Diagnostic Laboratories
  • 9.3. Hospitals & Clinics
  • 9.4. Research Institutes

10. Preterm Birth & PROM Testing Market, by Application

  • 10.1. Diagnosis
  • 10.2. Monitoring
  • 10.3. Research Use
  • 10.4. Screening

11. Preterm Birth & PROM Testing Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Preterm Birth & PROM Testing Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Preterm Birth & PROM Testing Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. Roche Diagnostics GmbH
    • 14.3.2. Abbott Laboratories
    • 14.3.3. Hologic, Inc.
    • 14.3.4. Quidel Corporation
    • 14.3.5. Danaher Corporation
    • 14.3.6. Thermo Fisher Scientific Inc.
    • 14.3.7. bioMerieux SA
    • 14.3.8. Sekisui Medical Co., Ltd.
    • 14.3.9. Sera Prognostics, Inc.
    • 14.3.10. Rhomed S.p.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. PRETERM BIRTH & PROM TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. PRETERM BIRTH & PROM TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PRETERM BIRTH & PROM TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY AUTOMATED ELISA ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY AUTOMATED ELISA ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY AUTOMATED ELISA ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY AUTOMATED ELISA ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY AUTOMATED ELISA ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY AUTOMATED ELISA ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PCR SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PCR SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PCR SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PCR SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PCR SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PCR SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ELISA KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ELISA KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ELISA KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ELISA KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ELISA KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ELISA KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PCR TEST KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PCR TEST KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PCR TEST KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PCR TEST KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PCR TEST KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PCR TEST KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RAPID TEST KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RAPID TEST KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RAPID TEST KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RAPID TEST KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RAPID TEST KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RAPID TEST KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BUFFERS & MEDIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BUFFERS & MEDIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BUFFERS & MEDIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BUFFERS & MEDIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BUFFERS & MEDIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BUFFERS & MEDIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ENZYMES & PROBES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ENZYMES & PROBES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ENZYMES & PROBES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ENZYMES & PROBES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ENZYMES & PROBES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ENZYMES & PROBES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY DIAGNOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY DIAGNOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY DIAGNOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY DIAGNOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY DIAGNOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RESEARCH USE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RESEARCH USE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RESEARCH USE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RESEARCH USE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RESEARCH USE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RESEARCH USE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 214. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2025-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 218. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 223. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 228. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 229. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2024 (USD MILLION)
  • TABLE 230. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2025-2032 (USD MILLION)
  • TABLE 231. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 232. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 233. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 236. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2024 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2025-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 258. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 259. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2024 (USD MILLION)
  • TABLE 260. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2025-2032 (USD MILLION)
  • TABLE 261. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 262. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 263. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 266. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 267. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 272. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 273. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2024 (USD MILLION)
  • TABLE 274. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2025-2032 (USD MILLION)
  • TABLE 275. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 276. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 277. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 280. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 295. BRICS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. BRICS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. BRICS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. BRICS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. BRIC